Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

4J THERAPEUTICS INC

UEI: SZCGV7LQJKR4CAGE: 9DFF0

4J THERAPEUTICS INC is a federal contractor, registered under UEI SZCGV7LQJKR4 and CAGE code 9DFF0. It has been awarded $37,589,800 across 1 federal contract. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

SZCGV7LQJKR4

CAGE Code

9DFF0

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

2X

NAICS Codes

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

4J Therapeutics Inc. specializes in the research and development of programmable antiviral technologies, focusing on the design, preclinical validation, and early-stage clinical evaluation of novel therapeutic platforms. Their core expertise lies in nucleic acid-based drug discovery, particularly le...

4J Therapeutics Inc. specializes in the research and development of programmable antiviral technologies, focusing on the design, preclinical validation, and early-stage clinical evaluation of novel therapeutic platforms. Their core expertise lies in nucleic acid-based drug discovery, particularly leveraging locked nucleic acid (LNA) chemistries to engineer targeted antiviral agents with high specificity and potency. The company develops end-to-end preclinical packages, including pharmacokinetic profiling, toxicology studies, and formulation science, to advance candidates into first-in-human Phase 1A trials. Their technical differentiator is the modular design of their platform, enabling rapid adaptation to emerging viral threats while maintaining robust safety and manufacturability profiles. This positions them at the intersection of molecular virology, oligonucleotide therapeutics, and translational medicine. The company has demonstrated direct engagement with the Department of Health and Human Services, where its work supports public health preparedness through the advancement of next-generation antiviral candidates. This relationship reflects a focus on mission-critical biodefense and infectious disease innovation aligned with HHS’s strategic priorities in pandemic response and biomedical R&D. 4J Therapeutics operates primarily within NAICS 541714, which encompasses biotechnology research aimed at therapeutic discovery and development outside of nanobiotechnology. Their vertical specialization is in antiviral platform technologies, with a clear emphasis on RNA-targeting modalities and early-phase clinical translation. This niche places them within the broader landscape of precision antiviral biotech, serving government-funded initiatives focused on novel therapeutic pipelines. As a small business structured as a 2L entity based in Palo Alto, California, 4J Therapeutics leverages its location within a global biotech hub to access scientific talent and research infrastructure. While currently holding no formal government certifications, its focused R&D model and direct engagement with HHS underscore its role as a specialized innovator in the federal biodefense and therapeutic development ecosystem.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services$37.6M100%
Awards by NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)$37.6M100%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in 4J THERAPEUTICS INC's top NAICS codes and agencies

NAICS: 541714
New
Federal
Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Solicitation # 75A50126R00001_RFP_PreSolNotice_NPIVS-2027
BARDA is seeking qualified contractors to support the ongoing Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program, requiring the provision of vaccines, antigens, and adjuvants to ensure rapid readiness for pandemic influenza or other viruses with pandemic potential. Contractors must deliver comprehensive services including manufacturing, regulatory documentation, and manufacturing readiness support, with a preference for U.S. based facilities. This includes generating and submitting all necessary analytical, nonclinical, clinical, and CMC data to the FDA, even during interpandemic periods, to enable timely regulatory decisions and sustain production capability. The program emphasizes continuous improvement of influenza vaccines with demonstrated feasibility and full lifecycle support from development through commercial-scale manufacturing. To be eligible, offerors must have a proven track record in influenza vaccine manufacturing, either by holding an active U.S. influenza vaccine license or by having successfully submitted a Biologics License Application for a seasonal or pandemic influenza vaccine. The solicitation, issued under number 75A50126R00001_RFP_PreSolNotice_NPIVS-2027, is open with a response deadline of August 15, 2026, and is administered by the Department of Health and Human Services through BARDA. All proposals must meet strict qualification criteria and align with the program’s goals of ensuring national preparedness, rapid response capacity, and regulatory compliance. Primary point of contact for inquiries is Laura Saddison at HHS.
Barda - Aspr / Daappo / Barda Dcma

POSTED

3 days ago

DEADLINE

in 13 days
View Details
NAICS: 541714
New
Federal
Convergence Special Notice
Solicitation # DARPA-SN-26-108
The Convergence program seeks to revolutionize environmental monitoring for defense operations by integrating synthetic biology and engineering to create advanced microbial biosensors capable of detecting chemical and pharmaceutical hazards in austere environments. Leveraging non-pathogenic microbial consortia built on well-characterized, safe host organisms like E. coli, the initiative focuses on developing modular biological systems that translate environmental inputs into standardized, detectable outputs. The program’s development follows a structured four-tiered approach, progressing from component-level design and integrated payload engineering to full system integration within a microbial chassis, ultimately aiming for a deployable platform ready for U.S. and international regulatory certification. This systematic progression ensures that each layer of functionality is rigorously validated before scaling to operational readiness. To enable safe, responsible, and globally viable deployment, the program includes a dedicated ecosystem of testing and collaboration. Performance and safety validation will first occur within the United States before exploring international adoption, with two specialized working groups guiding the process: one focused on navigating socio-political landscapes and local environmental regulations, and another managing cooperative use cases and deployment protocols with global allies. Administered by DARPA, the solicitation under number DARPA-SN-26-108 invites multidisciplinary teams in synthetic biology, environmental science, and engineering to contribute to this initiative, with responses due by August 6, 2026. The program is headquartered in Arlington, Virginia, and is led by Mark Salvador, with the goal of delivering a scalable, secure, and globally interoperable biosensor platform for the protection of military personnel.
Defense Advanced Research Projects Agcy

POSTED

3 days ago

DEADLINE

in 10 days
View Details
NAICS: 562111
New
Federal
Notice of Intent / Sole Source Solid Waste
Solicitation # 75H71026Q00223
The Navajo Area Indian Health Service, Shiprock Service Unit, intends to award a sole-source, firm-fixed-price contract to Navajo Sanitation for solid waste collection services at the Dzilth-Na-O-Dith-Hle Health Center in Bloomfield, New Mexico, with performance beginning September 1, 2026, and ending August 31, 2027. The procurement is justified under unusual and compelling urgency due to the contractor’s unique, uninterrupted history of providing essential waste management services at the facility, ensuring continuity of operations critical to patient care. The North American Industry Classification System code is 562111, with a small business size standard of $47 million in annual revenue. No competitive solicitation will be issued unless a respondent submits clear and convincing evidence that competition would benefit the government. Responses must be submitted in writing as a capability statement by August 17, 2026, at 10:00 a.m. MST, and must not include proprietary, classified, confidential, or sensitive information. The government is not obligated to respond to or acknowledge submissions, and failure to receive affirmative responses will result in contract award without further notice. All information provided may be used in future solicitations if competition is pursued, and any resulting solicitation will be publicly announced on SAM.gov. The point of contact for inquiries is Ken Parrish, Purchasing Agent, reachable at ken.parrish@ihs.gov.
Department Of Health And Human Services

POSTED

3 days ago

DEADLINE

in 16 days
View Details
NAICS: 541714
New
Federal
Multimodal Sensor Integration and Signal Fusion EngineeringThe contract seeks integration of multiple sensing modalities into a unified platform designed for real-time pharmaceutical inspection, emphasizing synchronized signal correlation and advanced noise reduction techniques. The project requires the engineering of a robust system capable of fusing data from diverse sensor types to enhance detection accuracy, reliability, and speed in identifying product defects or anomalies during manufacturing processes. Development must ensure temporal and spatial alignment of signals, adaptive filtering for environmental and operational interference, and seamless interoperability across hardware and software components to support continuous, high-fidelity monitoring. This subcontract, under NAICS code 541714 and sponsored by the Advanced Research Projects Agency for Health within the Department of Health and Human Services, targets innovation in sensor fusion technologies with a specific focus on quality assurance in pharmaceutical production. The place of performance is designated as Washington DC with a zip code of 20005, and proposals must be submitted by August 20, 2026. The initiative aims to advance detection capabilities beyond conventional single-sensor approaches, enabling next-generation inspection systems that meet stringent regulatory standards through data-driven, real-time analytics.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

5 days ago

DEADLINE

in 18 days
View Details
NAICS: 541714
New
Federal
Sources Sought – RRBS Sequencing Services
Solicitation # 36C241-26-AP-4037
The Department of Veterans Affairs is seeking qualified Service-Disabled Veteran-Owned Small Businesses and Veteran-Owned Small Businesses to provide Reduced Representation Bisulfite Sequencing services for a neurodegenerative disease research program involving approximately 269 de-identified human post-mortem choroid plexus tissue samples. The scope includes comprehensive sample handling and quality control, bisulfite conversion, library preparation, Illumina paired-end sequencing generating about 30 million read pairs per sample, and downstream bioinformatics analysis such as raw data alignment, methylation calling, and genome browser track generation, with an expected turnaround time of six to eight weeks. This notice is issued for market research purposes under the Veterans First Contracting Program and is intended to evaluate potential for a set-aside under the VA Rule of Two, ensuring opportunities for SDVOSBs and VOSBs. All interested parties must submit a capability statement detailing their technical expertise, business size and status as an SDVOSB or VOSB, and facility location by 11:00 AM EST on August 12, 2026, to Chelsea Cortright at Chelsea.Cortright@va.gov with the subject line referencing ID# 36C241-26-AP-4037. The opportunity is not a solicitation or request for proposals, and no contract will be awarded directly from this notice. The effort is managed by the 241-NETWORK Contract Office 01 based in Togus, Maine, with performance occurring in Bedford, Massachusetts, under NAICS code 541714 for analytical laboratory services. Additional inquiries can be directed to Jennifer Fiore, the secondary point of contact.
241-NETWORK Contract Office 01 (36C241)

POSTED

5 days ago

DEADLINE

in 10 days
View Details
NAICS: 541714
New
Federal
Research service necessary to execute a NAMRU SOUTH Zika study in Panama.
Solicitation # ERP_PR_1301393620
Naval Medical Research Unit South is seeking research services to support its Virology Department’s febrile and respiratory surveillance study, specifically in support of a Zika virus study in Panama. The government has conducted market research and determined that only Fundacion Ciudad del Saber possesses the unique capability to fully meet the technical and operational requirements of the study, making the procurement eligible for a sole source award under FAR 13.106-1(b)(i). No competitive solicitation exists, and this notice serves solely as an opportunity for other potential vendors to demonstrate their capability to perform the work. Interested parties must submit a capability statement not exceeding five pages in 10-point font or larger, containing detailed management, technical, and cost information with convincing evidence of their ability to fulfill the requirement. Submissions must be sent via email as a Word or PDF attachment to genaro.m.vasquez.ln@health.mil with the subject line “ERP PR_1301393620” no later than 12:00 PM local time on August 11, 2026. Responses consisting only of questions or requests for clarification will not be accepted. The government retains full discretion to proceed with a sole source award or open a competitive process based on the submissions received. The contracting office is located in Washington, DC, and the primary point of contact is Genaro Vasquez.
Naval Medical Research Unit South

POSTED

6 days ago

DEADLINE

in 9 days
View Details
NAICS: 541714
Federal
Humanized single domain antibodies for therapeutic brain delivery​
Solicitation # 75N98026Q00867
The National Institutes of Health Office of Extramural Research, under the Department of Health and Human Services, has issued a presolicitation for the development of humanized single domain antibodies designed for therapeutic delivery across the blood-brain barrier. The project, identified by solicitation number 75N98026Q00867, aims to advance novel antibody technologies capable of targeting brain-specific pathologies with enhanced precision and efficacy. All responses are due by August 3, 2026, and no set-aside provisions are applicable, meaning the opportunity is open to all eligible entities. The performance location is designated as Bethesda, Maryland, with the contract administration handled by the agency’s office at 20892. Primary point of contact for inquiries is Towanda Daniels, reachable via email at danielt@mail.nih.gov. The solicitation was posted on July 24, 2026, and all potential offerors are directed to the designated SAM.gov workspace for additional details and documentation. No NAICS code has been assigned at this stage, and the initiative reflects a strategic effort to enable breakthrough treatments for neurological disorders through innovative biotherapeutic platforms. Applicants must ensure full compliance with the requirements outlined in the attached Notice of Intent.
National Institutes Of Health Olao

POSTED

9 days ago

DEADLINE

in about 21 hours
View Details
NAICS: 541714
Grant
Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration AwardThe Congressionally mandated Clinical and Translational Science Awards (CTSA) Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by funding a national network of academic medical centers. This network provides essential infrastructure, expertise, training, and collaborative platforms needed to move research from the laboratory into clinical practice and community health settings. The current opportunity is a forecast for a limited competition soliciting applications for the Collaborative and Innovative Acceleration Award, designed to support the development and implementation of novel approaches, technologies, or models that amplify the impact of translational research and expedite the delivery of effective therapies to all populations. Funding is authorized under Sections 301 and 405 of the Public Health Service Act, and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Eligible organizations may apply under this limited competition, and proposals will undergo standard National Institutes of Health peer review, with funding awarded only to meritorious applications. The announcement is issued by the National Institutes of Health, under the Department of Health and Human Services, with specific inquiries directed to the Division of Clinical Innovation at NCATS. The forecast was posted on July 20, 2026, and further details can be accessed through the official grants.gov listing, though no set-aside type, NAICS code, or specific place of performance is indicated.
National Institutes Of Health

POSTED

13 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Federal
Hypoxia Chamber Services
Solicitation # 80JSC026Q0008
NASA Johnson Space Center is soliciting offers for Hypoxia Chamber Services under solicitation number 80JSC026Q0008 to support research on the physiological, cognitive, and clinical effects of mild hypobaric hypoxia as part of the Artemis Program. The contract requires comprehensive services including infrastructure, personnel, training, materials, food, supplies, and operational support necessary to conduct controlled hypoxia experiments. This is a combined synopsis and solicitation issued under FAR Subpart 12.6, with no written solicitation to follow, and all information is contained within the posted notice and attachments, particularly Attachment A for the Performance Work Statement and Attachment D for additional submission requirements. The NAICS code is 541714 with a size standard of 1,000 employees, and offerors must self-certify their size status. Evaluation will prioritize Technical Acceptability and Past Performance as significantly more important than Price, though Price becomes increasingly relevant when proposals are closely matched in technical merit. All submissions must include completed representations and certifications per FAR 52.212-3 and comply fully with FAR 52.212-1 and 52.212-4. Proposals must be submitted electronically via email to the designated NASA contacts no later than 1:00 PM CST on August 24, 2026, with questions due by July 29, 2026. The Government assumes no responsibility for electronic submission failures, and late submissions will be rejected per FAR provisions. The place of performance is Houston, Texas, and the Ombudsman clause is applicable for dispute resolution.
NASA Johnson Space Center

POSTED

17 days ago

DEADLINE

in 22 days
View Details
NAICS: 541714
Grant
Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain BarrierThe Eunice Kennedy Shriver National Institute of Child Health and Human Development is advancing its mission to improve maternal, fetal, and child health by launching a second phase of the Transporter Elucidation Network, focused on understanding how biological transporters and local metabolic processes regulate exposure to nutrients, medications, microbiome-derived compounds, and environmental chemicals across critical perinatal barriers. This initiative will develop comprehensive multi-barrier frameworks that connect the maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier, building on prior organ-specific research to create standardized models, resources, and prototype multi-compartment systems that reflect the dynamic interplay of transporters, their polarity, kinetics, and biotransformation capacities during pregnancy, lactation, and infant development. The goal is to deepen mechanistic insights into how these systems influence nutrient delivery, drug distribution, and neurodevelopmental outcomes in early life. This phase will establish community-wide resources to support integrated studies of perinatal exposure, risk assessment, and targeted interventions across linked maternal-fetal-infant systems, while strengthening collaboration among researchers and accelerating the sharing of tools and data. Emphasis is placed on human-based and developmentally relevant models to ensure biological accuracy and translational impact. The effort also aims to cultivate a next-generation workforce skilled in transporter science, fostering innovation in pediatric pharmacology and neonatal health. Authorized under 42 U.S.C. § 241, the initiative is being led by the Obstetric and Pediatric Pharmacology and Therapeutics Branch of NICHD, with inquiries directed to their designated point of contact, and the opportunity was publicly forecasted on July 16, 2026.
National Institutes Of Health

POSTED

17 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Federal
Hypobaric Chamber Pilot Studies
Solicitation # 80JSC026Q0006
NASA Johnson Space Center is soliciting offers for pilot chamber testing facilities capable of conducting hypobaric Decompression Sickness (DCS) studies under solicitation number 80JSC026Q0006, issued as a combined synopsis and solicitation per FAR Part 12 for commercial products and services. The requirement calls for three test days of data collection and recording following established research protocols, with detailed specifications outlined in Attachment A – Statement of Work and additional submission criteria in Attachment D dated July 15, 2026. The solicitation is open to all responsible sources without set-aside restrictions, and offerors must declare their size status under NAICS code 541714 with a 1,000-employee size standard. Evaluation of proposals will prioritize technical acceptability, followed by past performance, and then price, as specified in FAR 52.212-2. Offers must comply with applicable clauses including FAR 52.212-1, 52.212-2, and 52.212-4, as well as NASA-specific clauses such as the Ombudsman provision. All submissions must be delivered electronically to Tracy.L.Quintanilla@nasa.gov and Katelyn.R.Jaime@nasa.gov no later than August 24, 2026, at 1:00 p.m. Central Time. Questions must be submitted via email by July 29, 2026, same time, with no telephone inquiries accepted. Prospective offerors are encouraged to notify the point of contact of their intent to respond, and it is the offeror’s responsibility to download all documents from SAM.gov and ensure timely submission, as late or incomplete offers will be rejected in accordance with FAR provisions.
NASA Johnson Space Center

POSTED

18 days ago

DEADLINE

in 22 days
View Details